Ana I Matos, Carina Peres, Barbara Carreira, Liane I F Moura, Rita C Acúrcio, Theresa Vogel, Erik Wegener, Filipa Ribeiro, Marta B Afonso, Fábio M F Santos, Águeda Martínez-Barriocanal, Diego Arango, Ana S Viana, Pedro M P Góis, Liana C Silva, Cecília M P Rodrigues, Luis Graca, Rainer Jordan, Ronit Satchi-Fainaro, Helena F Florindo
Immune checkpoint blockade reaches remarkable clinical responses. However, even in the most favorable cases, half of these patients do not benefit from these therapies in the long term. It is hypothesized that the activation of host immunity by co-delivering peptide antigens, adjuvants, and regulators of the transforming growth factor (TGF)-β expression using a polyoxazoline (POx)-poly(lactic-co-glycolic) acid (PLGA) nanovaccine, while modulating the tumor-associated macrophages (TAM) function within the tumor microenvironment (TME) and blocking the anti-programmed cell death protein 1 (PD-1) can constitute an alternative approach for cancer immunotherapy...
July 11, 2023: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)